WALTHAM, Mass., May 14, 2009 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics, announced today that there
will be two presentations regarding trastuzumab-DM1 (T-DM1) at the 2009
Annual Meeting of the American Society of Clinical Oncology (ASCO) at
the Orange County Convention Center in Orlando, Florida. T-DM1 consists
of ImmunoGen's DM1 cancer-cell killing agent linked to the HER2-targeted
antibody, trastuzumab, developed by Genentech (a wholly-owned member of
the Roche Group). A broad T-DM1 clinical program is being conducted by
Genentech (US) and Roche (ex-US). Details regarding the titles, times
and locations of these presentations are provided below.
"The ASCO presentations on T-DM1 will expand the body of clinical data
reported on this highly promising compound," commented Daniel Junius,
President and Chief Executive Officer. "On May 30, the final results
will be presented from the 'second-line plus' Phase II trial in
HER2-positive metastatic breast cancer, which will build on the data
previously reported from this trial. This presentation has been selected
for the 'Best of ASCO(R)' program and will include objective
response, progression-free survival and duration of response data from
this 112-patient study. A separate presentation on June 1 will provide
expanded information on the relationship between HER2 expression and
response to T-DM1."
T-DM1 Presentations at the ASCO Annual Meeting
"A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug
conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC):
final results" (abstract #1017).
Poster presentation - May 30, 8:00 a.m. to 12 noon EDT, Level 2,
W240A, Board 9.
Poster discussion - May 30, 12:00 noon to 1:00 p.m. EDT, Level 2, West
"Quantitative assessment of HER2 status and correlation with efficacy
for patients with metastatic breast cancer (MBC) in a phase II study of
trastuzumab-DM1 (T-DM1)" (abstract #1003).
Oral presentation - June 1, 10:30 am, Level 2, West Hall D2.
In addition to these presentations on T-DM1, an abstract (#e15625) on
IMGN242 has been accepted by ASCO for publication (as submitted).
IMGN242 is in Phase II testing for the treatment of gastric cancer
expressing the CanAg antigen targeted by the compound.
The ASCO annual meeting is being held May 29-June 2, 2009 in Orlando,
Florida. Abstracts and other information about ASCO and this meeting may
be found at www.asco.org.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its
expertise in cancer biology, monoclonal antibodies and the creation and
linkage of potent cancer-cell killing agents (CKAs) to such antibodies.
The Company's proprietary Targeted Antibody PayloadTM (TAP)
technology consists of ImmunoGen's highly potent CKAs, which have been
designed specifically for delivery by antibodies to cancer cells, and
the Company's engineered linkers, which direct the activation of the CKA
inside a cancer cell. Compounds utilizing the TAP technology are in
clinical testing through ImmunoGen's own programs and its collaborations
with Genentech (a wholly-owned member of the Roche Group),
sanofi-aventis, Biogen Idec and Biotest. The most advanced compound,
T-DM1, is in Phase III testing being conducted by Genentech and Roche.
Other ImmunoGen collaborative partners include Bayer HealthCare and
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of products, including
trastuzumab-DM1, by our collaborators, including risks related to
uncertainties around clinical trials conducted and their timings and
results. A review of these risks can be found in ImmunoGen's Annual
Report on Form 10-K for the fiscal year ended June 30, 2008 and other
reports filed with the Securities and Exchange Commission.
Best of ASCO(R) is a registered trademark of the American
Society of Clinical Oncology.
SOURCE: ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations
and Corporate Communications